 |
|
|
| |
Impact of Pretreatment Plasma HBV DNA Levels on the Rate of ALT Normalization During Antiviral Therapy With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
| |
| |
AASLD 2020 Nov 11-16
Reported by Jules Levin
Young-Suk Lim,1 Jonggi Choi,1 Won-Mook Choi,1 Maurizia Brunetto,2 Jin-Lin Hou,3 Kosh Agarwal,4 Ting-Tsung Chang,5 Qin Ning,6 Seng-Gee Lim,7 Adrian Streinu-Cercel,8 John F. Flaherty,9 Hongyuan Wang,9 Bing Gao,9 Anuj Gaggar,9 Vithika Suri,9 Carla S. Coffin,10 Maria Buti,11 Henry L.Y. Chan12
References: 1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906;
3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40;
5. Agarwal K, et al. J Hepatol 2018;68:672-81; 6. Buti M, et al. Lancet Gastroenterol Hepatol 2016;1:196-206;
7. Chan HLY, et al. Lancet Gastroenterol Hepatol 2016;1:185-95; 8. Lampertico P, et al. EASL 2020, abstr 91;
9. Lampertico P, et al. Lancet Gastroenterol Hepatol 2020;5:441-53; 10. Choi J, et al. Am J Gastroenterol 2020;115:406-14;
11. Terrault NA, et al. Hepatology 2018;67:1560-99; 12. Wong GL, et al. J Hepatol 2018;69:793-802; 13. Fung S, et al. AASLD 2016, poster 1852;
14. Jacobson I, et al. Clin Gasteroenterol Hepatol 2017;15:1087-94.
|
| |
|
|
|
|
|
